Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CONNEQT HEALTH LIMITED
ABN	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Craig Cooper
Date of last notice	30 April 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<u>C2 Ventures Pty Ltd</u> Craig Cooper is a controller of this entity.
Date of change	25 June 2026

No. of securities held prior to change	Direct Interests • 2,000,000 Performance Rights expiring 30 November 2027 • 7,500,000 Performance Rights expiring 9 May 2030 • 10,000,000 Performance Rights expiring 31 August 2030 • 20,058,074 FPO C2 Ventures Pty Ltd • 202,695,062 FPO shares • 1,500,000 Convertible Note Options exercisable at $0.45 each, expiring 31 August 2026 • 2,000,000 Convertible Notes as approved by Shareholders at the 14 April 2026 EGM
Class	As above
Number acquired	C2 Ventures Pty Ltd • 101,010,102 FPO shares
Number disposed	NIL
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	**Acquired** C2 Ventures Pty Ltd • $2,000,000 – a face value of $1 per convertible note. The shares are issued following shareholder approval obtained on 14 April 2026, on the terms and conditions as outlined in the Notice of Meeting released on 12 March 2026.

No. of securities held after change	Direct Interests • 2,000,000 Performance Rights expiring 30 November 2027 • 7,500,000 Performance Rights expiring 9 May 2030 • 10,000,000 Performance Rights expiring 31 August 2030 • 20,058,074 FPO C2 Ventures Pty Ltd • 303,705,164 FPO shares • 1,500,000 Convertible Note Options exercisable at $0.45 each, expiring 31 August 2026 • 2,000,000 Convertible Notes as approved by Shareholders at the 14 April 2026 EGM
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	**Acquired** C2 Ventures Pty Ltd • 101,010,102 FPO shares upon conversion of the 2,000,000 convertible notes issued upon shareholder approval on 14 April 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A as no interest in contracts.
Nature of interest	N/A
Name of registered holder **(if issued securities)**	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No, as no securities traded.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CONNEQT HEALTH LIMITED
ABN	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Niall Cairns
Date of last notice	30 April 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	C2 Ventures Pty Ltd Niall Cairns is a controller of this entity. Carnethy Evergreen Pty Ltd Niall Cairns is the controller of this entity. Carnethy Investments Pty Ltd Niall Cairns is the controller of this entity.
Date of change	25 June 2026

No. of securities held prior to change	Direct Interests • 2,000,000 Performance Rights expiring 30 November 2027 • 7,500,000 Performance Rights expiring 9 May 2030 • 10,000,000 Performance Rights expiring 31 August 2030 • 1,250,000 FPO shares C2 Ventures Pty Ltd • 202,695,062 FPO shares • 1,500,000 Convertible Note Options exercisable at $0.45 each, expiring 31 August 2026 • 2,000,000 Convertible Notes as approved by Shareholders at the 14 April 2026 EGM Carnethy Evergreen Pty Ltd • 14,084,204 FPO shares • 200,000 Convertible Note Options exercisable at $0.45 each, expiring 31 August 2026 Carnethy Investments Pty Ltd • 14,581,638 FPO shares
Class	As above
Number acquired	C2 Ventures Pty Ltd • 101,010,102 FPO shares
Number disposed	NIL
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	**Acquired** C2 Ventures Pty Ltd • $2,000,000 – a face value of $1 per convertible note. The shares are issued following shareholder approval obtained on 14 April 2026, on the terms and conditions as outlined in the Notice of Meeting released on 12 March 2026.

+ See chapter 19 for defined terms.

No. of securities held after change	Direct Interests • 2,000,000 Performance Rights expiring 30 November 2027 • 7,500,000 Performance Rights expiring 9 May 2030 • 10,000,000 Performance Rights expiring 31 August 2030 • 1,250,000 FPO shares C2 Ventures Pty Ltd • 303,705,164 FPO shares • 1,500,000 Convertible Note Options exercisable at $0.45 each, expiring 31 August 2026 • 2,000,000 Convertible Notes as approved by Shareholders at the 14 April 2026 EGM Carnethy Evergreen Pty Ltd • 14,084,204 FPO shares • 200,000 Convertible Note Options exercisable at $0.45 each, expiring 31 August 2026 Carnethy Investments Pty Ltd • 14,581,638 FPO shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	**Acquired** C2 Ventures Pty Ltd • 101,010,102 FPO shares upon conversion of the 2,000,000 convertible notes issued upon shareholder approval on 14 April 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A as no interest in contracts.
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

+ See chapter 19 for defined terms.

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No, as no securities traded.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.